THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent private ...
CEO Michael Exton emphasized the company's focus on advancing R&D, stating, "We've successfully repositioned the company to really focus on R&D. We've achieved this focus by developing our innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results